1
|
Gao W, Zhou G, Li M, Wang P, Li J, Deng R. HIV drug resistance: analysis of viral genotypes and mutation loci in people living with HIV in Chongqing, China (2016-2023). AIDS Res Ther 2024; 21:62. [PMID: 39272106 PMCID: PMC11396324 DOI: 10.1186/s12981-024-00646-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2024] [Accepted: 08/14/2024] [Indexed: 09/15/2024] Open
Abstract
BACKGROUND Large-scale HIV genotype drug resistance study has not been conducted in Chongqing. METHODS A retrospective study was conducted on people living with HIV(PLWH) who received HIV-1 genotype resistance testing at Chongqing Public Health Medical Center from May 2016 to June 2023. The HIV-1pol gene was amplified through RT-PCR and analyzed in terms of genotypic drug resistance. RESULTS Of the 3015 PLWH tested for HIV-1 drug resistance, 1405 (46.6%) were resistant to at least one antiviral drug. Among non-nucleoside reverse transcriptase inhibitors (NNRTIs), 43.8% were resistant, compared to 29.5% for nucleoside reverse transcriptase inhibitors (NRTIs) and 3.4% for protease inhibitors (PIs). V179D/E and K103N/S were identified as the common mutation sites in the NNRTIs class of drugs, M184V/I and K65R/N were reported as the most common mutation sites in NRTIs, while thymidine analogue mutation (TAM) group was identified in 373 samples. L10FIV was the most common mutation in PIs. The dominant HIV-1 subtype was CRF07_BC. CONCLUSIONS The high prevalence of HIV-1 drug resistance in Chongqing underscores the imperative for rigorous surveillance of the local HIV epidemic. Furthermore, TAMs are associated with HIV-1 multidrug resistance, and timely detection of drug resistance is helpful to reduce the emergence and spread of such drug-resistant strains.
Collapse
Affiliation(s)
- Wenwan Gao
- Department of Medical Laboratory Medicine, Chongqing Public Health Medical Center, Chongqing, China
| | - Gang Zhou
- Department of Medical Laboratory Medicine, Chongqing Public Health Medical Center, Chongqing, China
| | - Mei Li
- Department of Medical Laboratory Medicine, Chongqing Public Health Medical Center, Chongqing, China
| | - Pengsen Wang
- Department of Medical Laboratory Medicine, Chongqing Public Health Medical Center, Chongqing, China
| | - Jungang Li
- Department of Medical Laboratory Medicine, Chongqing Public Health Medical Center, Chongqing, China
| | - Renni Deng
- Department of Medical Laboratory Medicine, Chongqing Public Health Medical Center, Chongqing, China.
| |
Collapse
|
2
|
Mangala C, Takou D, Maulot-Bangola D, Beloumou G, Rebienot Pellegrin O, Sosso SM, Ambe Chenwi C, Ngoufack Jagni Semengue E, Vigan Codjo F, Boussougou O, Nka AD, Tommo M, Fainguem N, Kamgaing R, Ama Moor V, Kamga Gonsu H, Penlap V, Nkoa T, Colizzi V, Perno CF, Fokam J, Ndjolo A. HIV-1 residual risk and pre-treatment drug resistance among blood donors: A sentinel surveillance from Gabon. PLoS One 2024; 19:e0305935. [PMID: 39226273 PMCID: PMC11371224 DOI: 10.1371/journal.pone.0305935] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2024] [Accepted: 06/06/2024] [Indexed: 09/05/2024] Open
Abstract
BACKGROUND Surveillance of HIV-1 pre-treatment drug resistance (PDR) is essential for ensuring the success of first-line antiretroviral therapy (ART). Beside population-based surveys, sentinel surveillance of PDR and circulating HIV-1 clades in specific populations such as blood donors could efficiently inform decision-making on ART program. We therefore sought to ascertain HIV-1 residual infection, the threshold of PDR and viral diversity among recently-diagnosed blood donors in Gabon. METHODS A sentinel surveillance was conducted among 381 consenting blood donors at the National Blood Transfusion Center (NBTC) in Gabon from August 3,2020 to August, 31, 2021. In order to determine the residual risk of HIV transmission, viral load and HIV-1 Sanger-sequencing were performed at the Chantal BIYA International Reference Center (CIRCB)-Cameroon on HIV samples previously tested seronegative with ELISA in Gabon. Phylogeny was performed using MEGA X, PDR threshold>10% was considered high and data were analysed using p≤0.05 for statistical significance. RESULTS Five HIV-negative blood donors had a detectable viral load indicating a high residual risk of HIV transmission. Among the samples successfully sequenced, four participants had major drug resistance mutations (DRMs), giving a threshold of PDR of 25% (4/16). By drug class, major DRMs targeting NNRTI (K103N, E138G), NRTIs (L210W) and PI/r (M46L). The most representative viral clades were CRF02_AG and subtype A1. The genetic diversity of HIV-1 had no significant effect on the residual risk in blood transfusion (CRF02_AG, P = 0.3 and Recombinants, P = 0.5). CONCLUSION This sentinel surveillance indicates a high residual risk of HIV-1 transfusion in Gabon, thereby underscoring the need for optimal screening strategy for blood safety. Moreover, HIV-1 transmission goes with high-risk of PDR, suggesting suboptimal efficacy of ART. Nonetheless, the genetic diversity has limited (if any effect) on the residual risk of infection and PDR in blood donors.
Collapse
Affiliation(s)
- Christian Mangala
- Chantal BIYA International Reference Centre for research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon
- School of Health Sciences, Catholic University of Central Africa (ESS-UCAC), Yaoundé, Cameroon
- Virology Department, National Public Health Laboratory (NPHL), Libreville, Gabon
| | - Désiré Takou
- Chantal BIYA International Reference Centre for research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon
| | - Denis Maulot-Bangola
- Chantal BIYA International Reference Centre for research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon
- School of Health Sciences, Catholic University of Central Africa (ESS-UCAC), Yaoundé, Cameroon
- Virology Department, National Blood Transfusion Centre (NBTC), Libreville, Gabon
| | - Grace Beloumou
- Chantal BIYA International Reference Centre for research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon
| | | | - Samuel Martin Sosso
- Chantal BIYA International Reference Centre for research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon
| | - Collins Ambe Chenwi
- Chantal BIYA International Reference Centre for research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon
- Faculty of Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy
| | | | - Franck Vigan Codjo
- Virology Department, National Blood Transfusion Centre (NBTC), Libreville, Gabon
| | - Olga Boussougou
- Virology Department, National Blood Transfusion Centre (NBTC), Libreville, Gabon
| | - Alex Durand Nka
- Chantal BIYA International Reference Centre for research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon
| | - Michel Tommo
- Chantal BIYA International Reference Centre for research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon
- School of Health Sciences, Catholic University of Central Africa (ESS-UCAC), Yaoundé, Cameroon
| | - Nadine Fainguem
- Chantal BIYA International Reference Centre for research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon
| | - Rachel Kamgaing
- Chantal BIYA International Reference Centre for research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon
| | - Vicky Ama Moor
- School of Health Sciences, Catholic University of Central Africa (ESS-UCAC), Yaoundé, Cameroon
- Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1 (FMBS-UY1), Yaoundé, Cameroon
- Laboratories of Biochemistry and Microbiology, University Teaching Hospital, Yaoundé, Cameroon
| | - Hortense Kamga Gonsu
- School of Health Sciences, Catholic University of Central Africa (ESS-UCAC), Yaoundé, Cameroon
- Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1 (FMBS-UY1), Yaoundé, Cameroon
- Laboratories of Biochemistry and Microbiology, University Teaching Hospital, Yaoundé, Cameroon
| | - Veronique Penlap
- School of Health Sciences, Catholic University of Central Africa (ESS-UCAC), Yaoundé, Cameroon
- Biotechnology Centre, University of Yaounde I, Yaounde, Cameroon
| | - Thérèse Nkoa
- School of Health Sciences, Catholic University of Central Africa (ESS-UCAC), Yaoundé, Cameroon
- Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1 (FMBS-UY1), Yaoundé, Cameroon
| | - Vittorio Colizzi
- Chantal BIYA International Reference Centre for research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon
- Faculty of Science and Technology, Evangelic University of Cameroon, Bandjoun, Cameroon
- UNESCO Chair of Biotechnology, University of Rome Tor Vergata, Rome, Italy
| | - Carlo-Federico Perno
- Chantal BIYA International Reference Centre for research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon
- Department of Microbiology, Bambino Gesu Pediatric Hospital, Rome, Italy
| | - Joseph Fokam
- Chantal BIYA International Reference Centre for research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon
- School of Health Sciences, Catholic University of Central Africa (ESS-UCAC), Yaoundé, Cameroon
- Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1 (FMBS-UY1), Yaoundé, Cameroon
- Faculty of Health Sciences, University of Buea (FHS-UB), Buea, Cameroon
- National HIV Drug Resistance working group, Ministry of Public Health, Yaounde, Cameroon
| | - Alexis Ndjolo
- Chantal BIYA International Reference Centre for research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon
- Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1 (FMBS-UY1), Yaoundé, Cameroon
| |
Collapse
|
3
|
Wang J, Li M, Li J, Deng R. Differences in drug resistance of HIV-1 genotypes in CSF and plasma and analysis of related factors. Virulence 2023; 14:2171632. [PMID: 36694270 PMCID: PMC9908293 DOI: 10.1080/21505594.2023.2171632] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
The emergence of HIV drug resistance seriously affects the quality of life of patients. However, there has been no extensive study of CSF resistance. The aim of this study is to evaluate common HIV-1 resistance in CSF and compare it with resistance in matched plasma, and analyse the influencing factors of cerebrospinal fluid drug resistance. The matched CSF and plasma samples of 62 HIV-1 patients were tested at one study site in China (Chongqing; 2019-2022). HIV genotyping and drug resistance was evaluated using the Stanford v8.7 algorithm. The diagnosis and treatment data and basic information were collected from the clinical case system, and the influencing factors of drug resistance mutations in CSF was obtained by variance analysis. CSF and matched plasma HIV-1 subtypes were confirmed in 62 patients, and the most frequent recombinant form was CRF07-BC (64.5%). Thirteen patients (21.0%) were detected with drug-resistant mutations, and the sites were consistent in both CSF and matched plasma. The drug-resistant ratios of untreated patients and treated patients were 5/51 (9.8%) and 8/11 (72.7%), respectively. The type with the highest mutation frequency was NNRTI, and no mutation was found in INSTI. Multivariate analysis indicated that ARV treatment was associated with CSF resistance (P < 0.001). The subtypes and drug resistance mutation sites are consistent in CSF and matched plasma samples of HIV-1 patients, and there is a correlation between ARV treatment and possible drug resistance, especially in CSF reservoirs. These findings highlight the concern about CSF drug resistance in HIV patients.
Collapse
Affiliation(s)
- Jie Wang
- Central lab, Chongqing Public Health Medical Center, Chongqing, China
| | - Mei Li
- Central lab, Chongqing Public Health Medical Center, Chongqing, China
| | - Jungang Li
- Central lab, Chongqing Public Health Medical Center, Chongqing, China
| | - Renni Deng
- Central lab, Chongqing Public Health Medical Center, Chongqing, China,CONTACT Renni Deng
| |
Collapse
|
4
|
Liu M, He XQ, Deng RN, Tang SQ, Harypursat V, Lu YQ, He K, Huo Q, Yang HH, Liu Q, Chen YK. Pretreatment drug resistance in people living with HIV: A large retrospective cohort study in Chongqing, China. HIV Med 2022; 23 Suppl 1:95-105. [PMID: 35293098 PMCID: PMC9311700 DOI: 10.1111/hiv.13253] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/14/2022] [Indexed: 12/24/2022]
Abstract
Objectives The emergence of pretreatment drug resistance (PDR) caused by increased usage of antiretroviral therapy (ART) represents a significant challenge to HIV management. In this study, we evaluated the prevalence of PDR in people living with HIV (PLWH) in Chongqing, China. Methods We retrospectively collected the data of 1110 ART‐naïve PLWH in Chongqing from January 1, 2018 to June 30, 2021. HIV‐1 genotypes and drug resistance were analyzed using the HIV‐1 pol sequence. Risk factors associated with PDR were evaluated via the logistic regression model. Results Nine genotypes were detected among 1110 participants, with CRF07_BC (55.68%) being the dominant genotype, followed by CRF01_AE (21.44%), CRF08_BC (14.14%), and other genotypes (8.74%). Of all the participants, 24.14% exhibited drug resistance mutations (DRMs). The predominant DRMs for non‐nucleoside reverse transcriptase inhibitors (NNRTIs) and nucleoside reverse transcriptase inhibitors (NRTIs) were V179D/E/A/DIN (13.60%) and M184V/I (1.44%), respectively, whereas only two major DRMs (M46L and I54L) were identified for protease inhibitors (PIs). The total prevalence of PDR was 10.54%, with 2.43%, 7.66%, and 1.71% participants exhibiting PDR to NRTIs, NNRTIs, and PIs, respectively. Furthermore, female PLWH, delays in ART initiation, and the CRF08_BC genotype were associated with a higher risk of PDR. Conclusions Our study provides the first large cohort data on the prevalence of PDR in Chongqing, China. HIV‐1 genotypes are diverse and complex, with a moderate level of PDR, which does not reach the threshold for the initiation of a public health response. Nevertheless, continuous surveillance of PDR is both useful and advisable.
Collapse
Affiliation(s)
- Min Liu
- Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China
| | - Xiao-Qing He
- Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China
| | - Ren-Ni Deng
- Department of Clinical Laboratory, Chongqing Public Health Medical Center, Chongqing, China
| | - Sheng-Quan Tang
- Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China
| | - Vijay Harypursat
- Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China
| | - Yan-Qiu Lu
- Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China
| | - Kun He
- Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China
| | - Qin Huo
- Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China
| | - Hong-Hong Yang
- Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China
| | - Qian Liu
- Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China
| | - Yao-Kai Chen
- Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.,Department of Clinical Laboratory, Chongqing Public Health Medical Center, Chongqing, China
| |
Collapse
|
5
|
Sun Z, Lan Y, Liang S, Wang J, Ni M, Zhang X, Yu F, Chen M, Zhang H, Yan L, Cai W, Lan G, Ma Y, Zhang F. OUP accepted manuscript. J Antimicrob Chemother 2022; 77:1119-1124. [PMID: 35134966 DOI: 10.1093/jac/dkac016] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2021] [Accepted: 12/28/2021] [Indexed: 11/13/2022] Open
Affiliation(s)
- Zhuoqun Sun
- Peking University Ditan Teaching Hospital, Beijing, China
- Capital Medical University Affiliated Beijing Ditan Hospital, Beijing, China
| | - Yun Lan
- Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China
| | - Shujia Liang
- Guangxi Key Laboratory of Major Infectious Disease Prevention and Control and Biosafety Emergency Response, Guangxi Center for Disease Control and Prevention, Nanning, China
| | - Jing Wang
- Chongqing Public Health Medical Center, Chongqing, China
| | - Mingjian Ni
- Xinjiang Center for Disease Control and Prevention, Xinjiang, China
| | - Xia Zhang
- Medical Laboratory Science Department of Weifang Medical College, Shandong, China
| | - Fengting Yu
- Capital Medical University Affiliated Beijing Ditan Hospital, Beijing, China
| | - Meiling Chen
- Capital Medical University Affiliated Beijing Ditan Hospital, Beijing, China
| | - Hanxi Zhang
- Capital Medical University Affiliated Beijing Ditan Hospital, Beijing, China
| | - Liting Yan
- Capital Medical University Affiliated Beijing Ditan Hospital, Beijing, China
| | - Weiping Cai
- Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China
| | - Guanghua Lan
- Guangxi Key Laboratory of Major Infectious Disease Prevention and Control and Biosafety Emergency Response, Guangxi Center for Disease Control and Prevention, Nanning, China
| | - Ye Ma
- National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Fujie Zhang
- Peking University Ditan Teaching Hospital, Beijing, China
- Capital Medical University Affiliated Beijing Ditan Hospital, Beijing, China
| |
Collapse
|
6
|
Franklyne JS, Gopinath PM, Mukherjee A, Chandrasekaran N. Nanoemulsions: The rising star of antiviral therapeutics and nanodelivery system-current status and prospects. Curr Opin Colloid Interface Sci 2021; 54:101458. [PMID: 33814954 PMCID: PMC8007535 DOI: 10.1016/j.cocis.2021.101458] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Nanoemulsions (NEs) of essential oil (EO) have significant potential to target microorganisms, especially viruses. They act as a vehicle for delivering antiviral drugs and vaccines. Narrowing of drug discovery pipeline and the emergence of new viral diseases, especially, coronavirus disease, have created a niche to use NEs for augmenting currently available therapeutic options. Published literature demonstrated that EOs have an inherent broad spectrum of activity across bacterial, fungal, and viral pathogens. The emulsification process significantly improved the efficacy of the active ingredients in the EOs. This article highlights the research findings and patent developments in the last 2 years especially, in EO antiviral activity, antiviral drug delivery, vaccine delivery, viral resistance development, and repurposing EO compounds against SARS-CoV-2.
Collapse
Affiliation(s)
| | | | - Amitava Mukherjee
- Centre for Nanobiotechnology, VIT University, Vellore, 32014, Tamil Nadu, India
| | | |
Collapse
|
7
|
Parczewski M, Sulkowska E, Urbańska A, Scheibe K, Serwin K, Grabarczyk P. Transmitted HIV drug resistance and subtype patterns among blood donors in Poland. Sci Rep 2021; 11:12734. [PMID: 34140600 PMCID: PMC8211697 DOI: 10.1038/s41598-021-92210-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2021] [Accepted: 06/07/2021] [Indexed: 12/17/2022] Open
Abstract
Surveillance on the HIV molecular variability, risk of drug resistance transmission and evolution of novel viral variants among blood donors remains an understudied aspect of hemovigilance. This nationwide study analyses patterns of HIV diversity and transmitted resistance mutations. Study included 185 samples from the first time and repeat blood donors with HIV infection identified by molecular assay. HIV protease, reverse transcriptase and integrase were sequenced using population methods. Drug resistance mutation (DRM) patterns were analyzed based on the Stanford Interpretation Algorithm and standardized lists of transmitted mutations. Phylogeny was used to investigate subtyping, clustering and recombination patterns. HIV-1 subtype B (89.2%) followed by subtype A6 (7.6%) were predominant, while in three (1.6%) cases, novel recombinant B/A6 variants were identified. Non-B variants were more common among repeat donors (14.5%) compared to the first time ones (1.8%), p = 0.011, with higher frequency (9.9%) of A6 variant in the repeat donor group, p = 0.04. Major NRTI DRMs were observed in 3.8%, NNRTI and PI in 0.6% and INSTI 1.1% of cases. Additionally, E157Q polymorphism was observed in 9.8% and L74I in 11.5% of integrase sequences. Transmission of drug resistance among blood donors remains infrequent. Subtype patters increase in complexity with emergence of novel intersubtype A6B recombinants.
Collapse
Affiliation(s)
- Miłosz Parczewski
- Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University, Arkońska 4, 71-455, Szczecin, Poland.
| | - Ewa Sulkowska
- Institute of Haematology and Transfusion Medicine in Warsaw, Warsaw, Poland
| | - Anna Urbańska
- Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University, Arkońska 4, 71-455, Szczecin, Poland
| | - Kaja Scheibe
- Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University, Arkońska 4, 71-455, Szczecin, Poland
| | - Karol Serwin
- Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University, Arkońska 4, 71-455, Szczecin, Poland
| | - Piotr Grabarczyk
- Institute of Haematology and Transfusion Medicine in Warsaw, Warsaw, Poland
| |
Collapse
|